News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
792,321 Results
Type
Article (56812)
Company Profile (404)
Press Release (735087)
Multimedia
Podcasts (160)
Webinars (23)
Section
Business (220898)
Career Advice (2950)
Deals (38242)
Drug Delivery (144)
Drug Development (88028)
Employer Resources (194)
FDA (17720)
Job Trends (16438)
News (376035)
Policy (36688)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2957)
Academic (1)
Accelerated approval (37)
Adcomms (34)
Allergies (158)
Alliances (54053)
ALS (185)
Alzheimer's disease (1810)
Antibody-drug conjugate (ADC) (356)
Approvals (17917)
Artificial intelligence (594)
Autoimmune disease (177)
Automation (44)
Bankruptcy (393)
Best Places to Work (12325)
BIOSECURE Act (23)
Biosimilars (210)
Biotechnology (249)
Bladder cancer (167)
Brain cancer (65)
Breast cancer (682)
Cancer (5170)
Cardiovascular disease (459)
Career advice (2499)
Career pathing (42)
CAR-T (307)
CDC (63)
Celiac Disease (2)
Cell therapy (819)
Cervical cancer (39)
Clinical research (74767)
Collaboration (1883)
Company closure (4)
Compensation (1214)
Complete response letters (76)
COVID-19 (2968)
CRISPR (104)
C-suite (936)
Cystic fibrosis (152)
Data (6488)
Decentralized trials (2)
Denatured (44)
Depression (157)
Diabetes (541)
Diagnostics (7151)
Digital health (51)
Diversity (13)
Diversity, equity & inclusion (47)
Drug discovery (284)
Drug pricing (224)
Drug shortages (35)
Duchenne muscular dystrophy (250)
Earnings (94734)
Editorial (68)
Employer branding (24)
Employer resources (167)
Events (127660)
Executive appointments (1060)
FDA (20997)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1569)
Gene editing (222)
Generative AI (53)
Gene therapy (672)
GLP-1 (1143)
Government (5256)
Grass and pollen (8)
Guidances (387)
Healthcare (20375)
HIV (68)
Huntington's disease (50)
IgA nephropathy (89)
Immunology and inflammation (302)
Immuno-oncology (70)
Indications (122)
Infectious disease (3273)
Inflammatory bowel disease (216)
Inflation Reduction Act (15)
Influenza (127)
Intellectual property (264)
Interviews (568)
IPO (17486)
IRA (59)
Job creations (4471)
Job search strategy (2035)
JPM (69)
Kidney cancer (18)
Labor market (91)
Layoffs (639)
Leadership (42)
Legal (9115)
Liver cancer (99)
Longevity (16)
Lung cancer (702)
Lymphoma (391)
Machine learning (44)
Management (65)
Manufacturing (870)
MASH (180)
Medical device (14588)
Medtech (14648)
Mergers & acquisitions (21851)
Metabolic disorders (1435)
Multiple sclerosis (174)
NASH (23)
Neurodegenerative disease (369)
Neuropsychiatric disorders (106)
Neuroscience (3180)
Neurotech (1)
NextGen: Class of 2026 (7237)
Non-profit (4967)
Now hiring (69)
Obesity (700)
Opinion (332)
Ovarian cancer (172)
Pain (221)
Pancreatic cancer (244)
Parkinson's disease (308)
Partnered (34)
Patents (535)
Patient recruitment (523)
Peanut (63)
People (64633)
Pharmaceutical (102)
Pharmacy benefit managers (34)
Phase 1 (23237)
Phase 2 (32720)
Phase 3 (24538)
Pipeline (5663)
Policy (340)
Postmarket research (2993)
Preclinical (9932)
Press Release (71)
Prostate cancer (255)
Psychedelics (59)
Radiopharmaceuticals (306)
Rare diseases (957)
Real estate (6719)
Recruiting (77)
Regulatory (27172)
Reports (58)
Research institute (2666)
Resumes & cover letters (464)
Rett syndrome (28)
RNA editing (18)
RSV (88)
Schizophrenia (165)
Series A (259)
Series B (202)
Service/supplier (13)
Sickle cell disease (106)
Special edition (28)
Spinal muscular atrophy (173)
Sponsored (45)
Startups (4028)
State (2)
Stomach cancer (21)
Supply chain (112)
Tariffs (101)
The Weekly (114)
Vaccines (1158)
Venture capital (98)
Weight loss (481)
Women's health (100)
Worklife (22)
Date
Today (164)
Last 7 days (722)
Last 30 days (2521)
Last 365 days (31748)
2026 (4416)
2025 (32069)
2024 (37212)
2023 (42099)
2022 (53395)
2021 (58092)
2020 (56911)
2019 (50186)
2018 (38035)
2017 (35170)
2016 (35225)
2015 (41226)
2014 (35449)
2013 (30748)
2012 (32662)
2011 (33234)
2010 (31387)
Location
Africa (978)
Alabama (93)
Alaska (7)
Arizona (329)
Arkansas (15)
Asia (46324)
Australia (8060)
California (11786)
Canada (3389)
China (1200)
Colorado (494)
Connecticut (506)
Delaware (351)
Europe (102417)
Florida (1765)
Georgia (374)
Hawaii (3)
Idaho (65)
Illinois (941)
India (76)
Indiana (550)
Iowa (23)
Japan (451)
Kansas (130)
Kentucky (42)
Louisiana (26)
Maine (72)
Maryland (1476)
Massachusetts (8587)
Michigan (347)
Minnesota (666)
Mississippi (6)
Missouri (141)
Montana (34)
Nebraska (28)
Nevada (127)
New Hampshire (84)
New Jersey (3158)
New Mexico (32)
New York (3117)
North Carolina (1602)
North Dakota (10)
Northern California (5736)
Ohio (355)
Oklahoma (22)
Oregon (47)
Pennsylvania (2359)
Puerto Rico (25)
Rhode Island (50)
South America (1371)
South Carolina (69)
South Dakota (1)
Southern California (4590)
Tennessee (182)
Texas (1821)
United States (42227)
Utah (353)
Vermont (1)
Virginia (291)
Washington D.C. (86)
Washington State (972)
West Virginia (4)
Wisconsin (130)
Wyoming (2)
792,321 Results for "s1 biopharma formerly known as s1 pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Alzheimer’s disease
In Novo’s GLP-1 Failure, Alzheimer’s Space Spies a Combination Opportunity
Despite the definitive failure of Novo Nordisk’s semaglutide in Alzheimer’s, biotech executives, analysts and other industry experts see potential in more testing of GLP-1s for the neurodegenerative disease, particularly in a combination approach.
January 2, 2026
·
5 min read
·
Annalee Armstrong
Funding
China’s Corxel Nabs $287M Series D1 to Bankroll GLP-1 Pill
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.
January 23, 2026
·
1 min read
·
Tristan Manalac
Drug pricing
As GLP-1s Hit Bargain Bin Prices, What’s the Future of the Obesity Market?
Novo Nordisk goes “on the offensive” following Trump deal that also included rival Eli Lilly, putting an exclamation point on rapidly declining GLP-1 drug prices. Experts say the unusual situation makes it hard to predict what’s next.
November 19, 2025
·
5 min read
·
Annalee Armstrong
Obesity
AstraZeneca’s China Trip Yields CSPC Obesity Deal Worth $1.2B Upfront
The pact, which could see AstraZeneca ultimately put out $18.5 billion in milestones and sales-based payments, is centered on SYH2082, a long-acting dual agonist of the GLP-1 and GIP receptors.
January 30, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Coloplast A/S - Interim Financial Report, Q1 2025/26
February 6, 2026
·
6 min read
Earnings
GSK Says No to GLP-1s, Prioritizes ‘Downstream Effects’ of Obesity
Instead of joining the increasingly crowded GLP-1 arena, GSK will focus its efforts downstream of obesity—a push currently anchored by its Phase III-ready FGF21 analog efimosfermin alfa for liver fibrosis.
February 4, 2026
·
2 min read
·
Tristan Manalac
Job Trends
Hiring Plans Show Promise for Biopharma Job Seekers:
BioSpace
Report
More biopharma organizations were actively recruiting at the end of 2025 than 2024, based on the new
BioSpace
employment outlook report. Areas in demand this year include research and development and clinical. Organizations are also prioritizing artificial intelligence hires.
January 29, 2026
·
5 min read
·
Angela Gabriel
Press Releases
CTT Pharmaceutical Holdings, Inc. Files Form S-1 Registration Statement and Advances Equity Line of Credit and Scientific Development Milestones
December 30, 2025
·
5 min read
Immunology and inflammation
Lilly Eyes Pipeline in a Product as GLP-1s Move Into I&I
In addition to claiming revenue of $19.3 billion for the fourth quarter, Eli Lilly executives offered a glimpse into their strategy to expand their GLP-1 franchise into the immunology and inflammation space, with trials currently underway in asthma, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
February 4, 2026
·
2 min read
·
Heather McKenzie
Neurodegenerative disease
VectorY Bets up to $1.2B+ That Shape’s Brain-Penetrant Capsids Are a Fit
VectorY Therapeutics will evaluate the use of SHP-DB1, a capsid developed by Shape Therapeutics, to deliver therapies to the brain, including VectorY’s developmental Huntington’s and Alzheimer’s disease treatments.
September 18, 2025
·
2 min read
·
Dan Samorodnitsky
1 of 79,233
Next
